NY-1010DATA
9.3.2021 11:02:10 CET | Business Wire | Press release
1010data , a provider of analytical intelligence and data sharing solutions to the retail, consumer goods and financial services markets, and Strategix CFT , a boutique consulting company that specializes in innovative retail technologies and comprehensive systems integration, announced today that they have entered into a strategic partnership to provide offerings that deliver enhanced customer insights. Targeted at Retailers and Consumer Packaged Goods (CPG) companies across the UK and Europe, the two companies will use their combined resources to develop analytics solutions that deliver the fastest predictive and prescriptive customer insights.
The new partnership will provide advanced data analytics technology driving best practices for large retailers to optimize and grow their business in this fast-changing market environment. This will include a single, powerful source of data enabling collaborative planning between retailers and suppliers. A single, integrated analytics platform empowering fast decisions putting forth the proper range of products and marketing effectively to inspire the customer while enhancing efficiencies across the supply chain. 1010data and Strategix will join forces driving ROI and value to retail and CPG companies with a better understanding of customers through big data analytic solutions driven by machine learning and AI.
“We are delighted to partner with Strategix as the need for our combined expertise is higher than ever,” said Inna Kuznetsova, CEO of 1010data . “Consumer shopping patterns have significantly changed during the pandemic and continue to evolve. As schools and businesses open in different locations at different times under different conditions, these changes will necessitate faster reactions at a more localized level. Retailers need to take the consumer’s pulse at ever shorter intervals and constantly re-optimize range, sales, promotions, marketing and supply chains. As we expand our European operations, the combined know-how of 1010data and Strategix will open up new avenues for retailers to identify opportunities for growth, while better serving their customers.”
Based upon 1010data’s Insights Platform, which combines granular analytics, data dashboards and collaboration portals, and then integrating Strategix’s expertise in category management, space optimization and supply chain analytics, the resulting offering will empower clients to make faster, better-informed decisions derived from their own customer data.
“Our two companies are a perfect complement to each other,” notes Jan Hanussek, CEO of Strategix CFT . “1010data’s Insights Platform for data management and collaboration fits perfectly with our proven strengths in retail consulting, systems integration, and bespoke application development. This will allow us to serve up our experience with retailers working across the UK and European marketplace, delivered on a supercharged tech platform provided by 1010data.”
“The partnership potential was obvious from our very first conversation with Strategix,” added Dusan Rnic, Vice President, Europe of 1010data . “With both the importance and scale of data growing exponentially, our partnership enables retailers to directly improve their agility as well as deliver upstream benefits to CPGs through market-leading, data-sharing solutions.”
About 1010data
For more than 20 years, 1010data has helped financial, retail and CPG companies monitor shifts in consumer demand and market conditions and rapidly respond with highly targeted strategies. The 1010data Insights Platform combines market intelligence, data management, granular enterprise analytics, and collaboration capabilities to empower better business outcomes. More than 900 of the world's foremost brands partner with 1010data to power smarter decisions. To learn more, visit www.1010data.com .
About Strategix CFT
Strategix CFT is a boutique consulting company and system integrator in the areas of Category Management and Supply Chain Management. With more than 20 years of experience Strategix relies on a deep subject matter expertise of technical and business process related themes. In order to ensure the solution meet customer needs in the best possible way Strategix provides hybrid/ multi-vendor solutions. Strategix has already helped leading retailers and manufacturers worldwide to execute a seamlessly integrated solutions in areas of category management and supply chain. Find out more at http://www.strategix.eu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005381/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom